Nirmalya Roy Moulik, Swaminathan Keerthivasagam, Ankita Pandey, Jayesh Agiwale, Kriti Hegde, Gaurav Chatterjee, Chetan Dhamne, Maya Prasad, Akanksha Chichra, Shyam Srinivasan, Purvi Mohanty, Hemani Jain, Dhanlaxmi Shetty, Prashant Tembhare, Nikhil Patkar, Gaurav Narula, Papagudi G Subramanian, Shripad Banavali
Tyrosine kinase inhibitors (TKIs) have drastically improved the outcomes of pCML (paediatric CML) but data on long-term off-target toxicities of TKIs in children are scarce. In this single-centre, retrospective cum prospective study of pCML in chronic phase, we report our experience of treating 173 children with imatinib and following them for long-term toxicities. Mean (SD) time to attain CHR, CCyR and MMR were 3.05 (2.1), 10.6 (8.4) and 43.4 (31.8) months respectively. DMR was not attained in 59 (34%) patients at last follow-up...
December 14, 2023: British Journal of Haematology